The impact of preoperative atrial fibrillation on survival and outcomes in heartmate II and heartmate 3 patients

Von der Medizinischen Fakultät
der Rheinisch-Westfälischen Technischen Hochschule Aachen
zur Erlangung des akademischen Grades
eines Doktors der Medizin
genehmigte Dissertation

vorgelegt von

Rami Al-Khusein

aus

Kamischli (Syrien)

Berichter: Priv. -Doz. Dr. med. Rachad Zayat
Prof. Dr. med. Ertunc Altiok

Tag der mündlichen Prüfung: 29.05.2026

Diese Dissertation ist auf den Internetseiten der Universitätsbibliothek online verfügbar.

Die Publikation die die Dissertation darstellt

Al-Khusein, R., Kolashov, A., Marx, N., Moza, A., Abugameh, A., Mohamed, Y. I., Al-Ahmed, A., Shoaib, M., Dogan, L., Zayat, R., & Khattab, M. A. (2025). The impact of preoperative atrial fibrillation on survival and outcomes in heartmate II and heartmate 3 patients. *BMC cardiovascular disorders*, *25*(1), 236. https://doi.org/10.1186/s12872-025-04680-1

BMC Cardiovascular Disorders

RESEARCH Open Access

The impact of preoperative atrial fibrillation on survival and outcomes in heartmate II and heartmate 3 patients

Rami Al-khusein[1*†], Alish Kolashov[2,3†], Nikolaus Marx[1], Ajay Moza[2], Ahmad Abugameh[4,5], Yousif Ibrahim Mohamed[6], Assila Al-Ahmed[7], Mohammed Shoaib[8], Leyla Dogan[2], Rashad Zayat[2†] and Mohammad Amen Khattab[2†]

Abstract

Background Atrial fibrillation (AF) is prevalent among patients with left ventricular assist devices (LVADs); however, the exact influence of different types of AF on the clinical outcomes of these patients is unknown. The purpose of this study was to ascertain the impact of different types of AF on the outcomes of patients with LVADs.

Methods The records of 162 patients with the LVADs HeartMate 3 ($n=64$) and HeartMate II ($n=98$) at a single center were reviewed. Kaplan–Meier survival analysis and Cox proportional hazards regression were used to analyze the associations among paroxysmal atrial fibrillation (pAF), permanent atrial fibrillation (peAF), survival, hemorrhage, and thromboembolism. To adjust for confounding factors, we also used the inverse probability of treatment weighting (IPTW) method and estimated the average treatment effect (ATE) for the outcomes of ischemic stroke (IS), mortality and right heart failure (RHF). Clinical trial number: not applicable.

Results Of the 56 (34.6%) patients with preoperative AF, 38 patients had pAF and 18 patients had peAF. Overall survival differed significantly among the three groups (log-rank test: $p=0.001$). Patients with peAF or pAF had a greater incidence of postoperative right heart failure (RHF) than did patients with sinus arrhythmia (SR) ($p=0.037$). According to the univariate and multivariate Cox regression analyses, both pAF and peAF were independent risk factors for post-LVAD IS (hazard ratio [HR]: 3.65 (95% CI: 1.28-10.41, $p=0.016$ and HR: 9.48 (2.94-30.56), $p<0.001$). Patients with preoperative peAF or pAF who received an LVAD did not have an increased risk for hemorrhagic stroke. After IPTW, the ATE with respect to mortality was significantly different between patients with peAF and those with SR ($p<0.001$). The ATE with respect to post-LVAD IS was significantly different for the pAF vs. SR and the peAF vs. SR patient groups ($p=0.035$ and $p=0.004$). After IPTW, the ATE for the RHF outcome did not significantly differ among the three groups.

†Rami Al-khusein and Alish Kolashov contributed equally to this work as first authors.

†Rashad Zayat and Mohammad Amen Khattab contributed equally to this work as last authors.

*Correspondence:
Rami Al-khusein
ralkhusein@ukaachen.de

Full list of author information is available at the end of the article

© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Conclusions Patients with preoperative pAF or peAF who underwent LVAD implantation had a higher risk of IS than patients with SR. Our data demonstrated that only preoperative peAF is associated with poor survival while SR is not.

Keywords Left ventricular assist device, Atrial fibrillation, HeartMate 3, HeartMate II, Ischemic stroke, Survival

Background

Left ventricular assist devices (LVADs) for patients with end-stage heart failure (HF) are now recognized as an acceptable treatment modality [1, 2]. Despite the notable enhancements in survival rates, functional capabilities, and quality of life that LVADs offer, their implementa- tion frequently coincides with severe adverse events such as cerebrovascular accidents (CVAs), pump thrombosis (PT), and major infections [3, 4].

As many as 50% of HF patients have atrial fibrillation (AF) [5], which has been linked to poorer outcomes and higher mortality in these patients [6]. The occurrence of AF or atrial flutter in patients with LVAD is significant, as documented incidence rates range from 21 to 72% [7, 8]. Multiple studies have presented findings on the out- comes of patients with preoperative AF who have LVADs compared with those of individuals without AF. However, these studies have yielded inconsistent results [7, 8, 9, 10].

Therefore, the objective of this study was to analyze the effects of different types of preoperative AF (paroxysmal AF (pAF) and permanent AF (peAF)) on the survival rate and occurrence of adverse events in HeartMate II (HMII) and Heartmate 3 (HM3) patients.

Methods

We retrospectively reviewed the medical records of adult patients who underwent HMII or HM3 implantation in our department between January 2012 and December 2021.

The clinical course and information regarding LVAD implantation were obtained from our institutional data- base. In addition to demographic and clinical data, we examined our database for preoperative cardiac rhythm, preoperative and postoperative laboratory data, and the incidence of adverse events, including bleeding and thromboembolism.

Our retrospective data analysis received approval from the ethics committee of our institution (Ethikkommis- sion-RWTH Aachen, IRBP 10/2014, EK151/09-Ver- sion-1.3). Due to the retrospective nature of our study, informed consent was waived by our institutional ethics board.

AF and anticoagulation

To assess the occurrence of pre- and postoperative atrial fibrillation (AF), retrospective chart evaluations, which included apparatus interrogations, progress notes, and electrocardiogram findings, were conducted. AF can be categorized into two subtypes, paroxysmal atrial fibril- lation (pAF) and permanent atrial fibrillation (peAF), according to established definitions [5]. Due to poten- tial variations in results between these categories, the patients were categorized into three groups for analysis:
(1) individuals with sinus arrhythmia (SR); (2) individuals with pAF; and (3) individuals with peAF. The HF special- ist was given the authority to determine how to treat AF after LVAD implantation. All patients were administered a daily dose of 100 mg of aspirin and warfarin for anti- coagulation. The target international normalized ratio (INR) range for HMII patients without AF was 2.5–3.0, while for HM3 patients, the range was 2.0–2.5. The INR range for all patients with atrial fibrillation (AF) was set at 2.5–3.0 for both HMII and HM3 devices. If a patient with AF experienced numerous instances of bleeding, the target INR was reduced to a range of 1.8–2.0.

AF and outcomes

This study aimed to investigate the effects of pAF and peAF on three primary outcomes: survival, thrombo- embolic events, and bleeding. All patient deaths were verified by reviewing the medical records, and the spe- cific cause of death was documented. Major bleeding, PT and right heart failure (RHF) were defined based on the updated 2021 version of the Thoracic Surgeon Inter- agency Registry of Mechanically Assisted Circulatory Support (STS-Intermacs) [11].

Statistical analysis

Categorical variables are presented as absolute numbers and percentages. The chi-square test or Fisher's exact test was used to examine categorical variables. The Kol- mogorov–Smirnov test was used to test for a normal dis- tribution. The t test or Mann–Whitney U test was used to evaluate continuous data where appropriate. Normally distributed continuous variables are presented as the means ± standard deviations. Nonnormally distributed variables are represented as medians with interquartile ranges (IQRs). Kaplan–Meier time-to-event curves were generated for death and ischemic stroke (IS) and were stratified by AF state. The statistical significance between the curves was assessed via the log-rank test, after which we used the Bonferroni method to adjust for multiple comparisons among the three groups. A linear regression analysis was performed to detect whether pAF or peAF had an effect on postoperative right heart failure (RHF). Cox proportional hazards univariable and multivari- able regression analyses were conducted to examine the

impact of preoperative AF and other known risk factors for AF on postoperative outcomes.

Known risk factors with a p value of < 0.05 in the uni- variable analysis were included in the multivariable model. To adjust for observed confounding factors in our observational study, we used the inverse probability of treatment weighting (IPTW) method, which has two primary stages. Initially, the probability—or propensity— of exposure to the relevant risk factor or intervention is determined on the basis of an individual's attributes (i.e., propensity score). Then, weights are determined as the reciprocal of the propensity score. The use of these weights for the research population generates a pseudo population whose confounders are uniformly distributed between exposed and unexposed groups [12]. Due to its resemblance to randomized controlled trials, inverse probability of treatment weighting (IPTW) is extensively employed in comparative effectiveness research [12]. After performing IPTW, we estimated the average treat- ment effect (ATE) in our population using SR, pAF and peAF as treatments after adjusting for age, sex, preopera- tive kidney disease, diabetes mellitus, hypertension, and ischemic cardiomyopathy (ICM). We estimated the aver- age treatment effect in our population via the abovemen- tioned method using post-LVAD ischemic stroke (IS), mortality, and post-LVAD RHF as outcomes.

All p values were 2-tailed, and the level of significance for all p values was < 0.05. All analyses were conducted via R statistics in R Studio interface version 4.0.3 (RStu- dio Team, Boston, MA) in conjunction with the jamovi project (2020) (jamovi computer software, version 2.3.9; JAMovi.org), which may be accessed at https://www.jam ovi.org/.

Results

A total of 162 patients (19.1% were female) diagnosed with end-stage heart failure underwent LVAD implanta- tion and received either the HM3 (n = 64) or the HMII (n = 98) device at our institution during the study period. A total of 73.5% of the patients experienced ischemic cardiomyopathy (ICM), while 26.5% had dilated car- diomyopathy (DCM). The mean follow-up time was 24.4 ± 20.5 months. Preoperatively, sinus arrhythmia (SR) was documented in 106 patients, and AF was docu- mented in 56 patients. Thirty-eight (23.4%) patients had pAF and 18 (11.1%) patients had peAF before implanta- tion. In all, 13.2% of the patients in the SR group, 23.7% in the pAF group and 44.4% in the peAF group were female (p = 0.006). Table 1 displays the patients' preop- erative clinical and demographic information. Patients in the pAF and peAF groups were significantly older than those in the SR group (63.6 ± 8.9 years vs. 64.3 ± 7.0 years vs. 60.1 ± 9.4 years, p = 0.045). Patients in the SR group had a significantly greater incidence of ICM as a cause of heart failure than did patients in the pAF and peAF groups (p = 0.007). However, patients with pAF or peAF had a significantly greater incidence of DCM (p = 0.012) (Table 1). Patients with pAF or peAF also had significantly greater incidences of preoperative kidney disease (KD) than did patients with SR (42.1% vs. 55.6% vs. 27.4%, p = 0.031) and had higher levels of preopera- tive creatinine (SR: 1.2 ± 0.9 mg/dL vs. pAF: 1.6 ± 0.7 mg/ dL vs. peAF: 1.5 ± 0.5 mg/dL, p = 0.049). Preoperatively, left atrium appendage (LAA) thrombus was detected through transesophageal echocardiography in 3 patients in the pAF group and in 2 patients in the peAF group among the remaining patients in the SR group (p = 0.003). The distribution of the performed operative procedures did not differ among the three groups (Table 2); only the percentage of patients who underwent LVAD implanta- tion plus LAA closure was significantly greater in the pAF and peAF groups because the LAA thrombus was detected preoperatively in these patients (SR: 0 vs. pAF: 7.9% vs. 11.1%, p = 0.006).

Atrial fibrillation and clinical outcomes

The mean survival time was 31.2 ± 19.5 months in the SR group, 15.8 ± 17.6 months in the pAF group and 3.2 ± 7.1 months in the peAF group. Overall survival dif- fered significantly among the three groups (log-rank test: p < 0.001) (Fig. 1). When we compared the pAF group with the SR group, we found that patients with pAF had a significantly lower probability of survival (log-rank: p = 0.031), and when we compared the peAF group with the SR group, we observed a significantly lower probabil- ity of survival in those with peAF (log-rank: p = 0.001). Table 2 summarizes the postoperative outcomes of all patients. The incidence of postoperative pneumonia and sepsis did not differ among the groups (Table 2). Patients with preoperative pAF or peAF had a greater incidence of postoperative RHF than did patients with SR (SR: 7.5% vs. pAF: 13.2% vs. peAF: 27.8%, p = 0.037). Patients with preoperative pAF or peAF also had longer ICU stays than patients with preoperative SR (pAF: 23.4 ± 23.1 days vs. peAF: 15.8 ± 14.1 days vs. SR: 13.9 ± 17.1 days, p = 0.026).

A total of 31.1% of patients with SR, 55.3% of patients with pAF and 72.2% of patients with peAF had postop- erative KD (p = 0.001). The incidence of postoperative ischemic stroke (IS) was significantly greater in both the pAF and peAF groups than in the SR group (18.4% vs. 27.7% vs. 6.6%, p = 0.012). The frequency of postoperative hemorrhagic stroke (HS) did not differ among the three groups (Table 2). The incidence of pump thrombosis also did not differ among the three groups. Patients with pre- operative pAF or peAF had a greater incidence of retho- racotomy than did those in the SR group (31.6% vs. 27.8% vs. 12.3%, p = 0.018). At hospital discharge, all laboratory data were similar among the three groups, despite the

Table 1 Patient demographics and preoperative data

	SR (*n* = 106)	pAF (*n* = 38)		peAF (*n* = 18)	*P*
Age (years)	60.1 ± 9.4	63.6 ± 8.9		64.3 ± 7.0	**0.045**
Female n (%)	14 (13.2)	9 (23.7)		8 (44.4)	**0.006**
BMI kg/m^2	27.4 ± 4.6	27.9 ± 4.4		27.5 ± 4.2	0.855
HeartMate 3 n (%)	33 (31.1)	21 (55.3)		10 (55.6)	**0.011**
HeartMate II n (%)	73 (68.9)	17 (44.7)		8 (44.4)	**0.011**
ICM n (%)	85 (80.2)	21 (55.3)		11 (61.1)	**0.007**
DCM n (%)	19 (17.9)	15 (39.5)		7 (38.9)	**0.012**
EF (%)	19.4 ± 5.7	20.1 ± 4.6		20.2 ± 5.0	0.682
IDDM n (%)	13 (12.3)	10 (26.3)		5 (27.8)	0.066
PAD n (%)	24 (22.6)	10 (26.3)		7 (38.9)	0.337
CVD n (%)	24 (22.6)	3 (7.9)		2 (11.1)	0.092
Nicotine n (%)	64 (60.4)	20 (52.6)		9 (50.0)	0.565
AHT n (%)	76 (71.7)	28 (73.7)		17 (94.4)	0.120
Preop IS n (%)	3 (2.8)	3 (7.9)		2 (11.1)	0.205
Hyperlipidemia n (%)	48 (45.3)	19 (50.0)		7 (38.9)	0.731
KD n (%)	29 (27.4)	16 (42.1)		10 (55.6)	**0.031**
Preop dialysis n (%)	7 (6.7)	2 (5.3)		0 (0.0)	0.521
COPD n (%)	30 (28.3)	13 (34.2)		4 (22.2)	0.629
PH n (%)	64 (60.4)	23 (60.5)		13 (72.2)	0.624
Beta-Blocker n (%)	66 (62.3)	25 (65.8)		13 (72.2)	0.698
Digitalis n (%)	13 (12.3)	15 (39.5)		10 (55.6)	**< 0.001**
Amiodarone n (%)	17 (16.0)	30 (78.9)		4 (22.2)	**< 0.001**
Prior eCV n (%)	0 (0.0)	16 (42.1)		8 (44.4)	**< 0.001**
LAA thrombus	0 (0.0)	3 (7.9)		2 (11.1)	**0.006**
Prior cardiac surgery n (%)	12 (16.4)	5 (29.4)		0 (0.0)	0.178
Prior PCI n (%)		36 (34.0)	16 (42.1)	10 (55.6)	0.188
Detected thrombus on LAA		0	4 (10.5)	4 (22.2)	< 0.001
INTERMACS profile n (%)					
I	13 (12.3)	4 (10.5)		1 (5.6)	0.101
II	15 (14.2)	5 (13.2)		2 (11.1)	
III	15 (14.2)	11 (28.9)		8 (44.4)	
IV	63 (59.4)	18 (47.4)		7 (38.9)	
Preoperative laboratory data:					
LDH U/L	228 (198, 303)	241 (202, 315)		226 (211, 298)	0.898
AST U/L	31.0 (22.0, 48.5)	28.5 (22.0, 52.0)		26.0 (19.2, 54.0)	0.729
ALT U/L	34.5 (20.0, 66.2)	30.5 (25.2, 53.2)		23.5 (17.8, 35.5)	0.159
Hb mg/dL	12.4 ± 2.4	12.0 ± 2.4		12.2 ± 1.6	0.765
Platelet counts G/L	226 (183, 288)	199 (141, 277)		211 (185, 312)	0.065
INR	1.1 ± 0.2	2.1 ± 0.2		2.3 ± 0.2	**< 0.001**
NT-pro-BNP pg/mL	2496 (1417, 7863)	2411(1925, 8251)		2900 (2900, 6064)	0.715
Creatinine mg/dL	1.2 ± 0.9	1.6 ± 0.7		1.5 ± 0.5	**0.049**

Continuous data are presented as the mean ± SD or as the median (25th, 75th percentiles) where appropriate. ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; BSA: body surface area; COPD: chronic obstructive pulmonary disease; CVD: cerebrovascular disease; DCM: dilated cardiomyopathy; DM: diabetes mellitus; eCV: electric cardioversion; EF: ejection fraction; Hb: hemoglobin; ICM: ischemic cardiomyopathy; ICU: intensive care unit; INR: international normalized ratio; INTERMACS: Interagency Registry for Mechanically Assisted Circulatory Support; KD: kidney disease; LAA: left atrium appendage; LDH: lactate dehydrogenase; NT-pro-BNP: N-terminal pro-brain natriuretic peptide; PAD: peripheral arterial disease; PCI: percutaneous coronary intervention; PH: pulmonary hypertension; pAF: paroxysmal atrial fibrillation; peAF: permanent atrial fibrillation; SR: sinus arrhythmia. Bold text indicates a significant *p* value

different INR values, which were significantly greater in the pAF and peAF groups than in the SR group (2.8 ± 0.3 vs. 2.9 ± 0.2 vs. 2.2 ± 0.3, $p < 0.001$).

After entering age, sex, ICM, DCM, preoperative KD, preoperative creatinine and the preoperative AF status in the univariate and multivariate Cox regression analyses to explore whether the preoperative AF type is an inde- pendent risk factor for post-LVAD mortality (Table 3), we found a significantly greater association between pAF and an increased risk of mortality than between SR and increased mortality risk (hazard ratio [HR]: 2.62 (1.37–5.02, $p = 0.004$)) (Fig. 2; Table 3). Patients with

Table 2 Perioperative data and postoperative course

	SR *n* = 106	pAF *n* = 38	peAF *n* = 18	*P*
LVAD alone n (%)	67 (63.2)	24 (63.2)	9 (50.0)	0.555
LVAD + LAA closure	0 (0.0)	3 (7.9)	2 (11.1)	**0.006**
LVAD + CABG n (%)	33 (31.4)	8 (21.1)	3 (16.7)	0.263
LVAD + TVR n (%)	4 (3.8)	2 (5.3)	3 (16.7)	0.087
LVAD + AVR n (%)	2 (2.3)	1 (4.8)	1 (10.0)	0.412
Pneumonia n (%)	44 (41.5)	24 (63.2)	9 (50.0)	0.070
Sepsis n (%)	41 (38.7)	21 (55.3)	6 (33.3)	0.151
ICU stay (days)	13.9 ± 17.1	23.4 ± 23.1	15.8 ± 14.1	**0.026**
Postoperative RHF	8 (7.5)	5 (13.2)	5 (27.8)	**0.037**
Postop KD n (%)	33 (31.1)	21 (55.3)	13 (72.2)	**0.001**
Postop ischemic stroke n (%)	7 (6.6)	7 (18.4)	5 (27.7)	**0.012**
Hemorrhagic stroke n (%)	1 (0.9)	1 (2.6)	1 (5.6)	0.374
TIA n (%)	9 (8.5)	0 (0.0)	0 (0.0)	0.228
Hemothorax n (%)	13 (12.3)	12 (31.6)	5 (27.8)	**0.018**
GI-Bleeding n (%)	7 (6.6)	2 (5.3)	0 (0.0)	0.525
LVAD thrombus n (%)	8 (7.5)	0 (0.0)	2 (11.1)	0.165
Laboratory data before discharge:				
LDH U/L	356 (296, 453.)	313.5 (276.5, 383)	411 (325.5, 549)	0.056
AST U/L	29 (22, 40.2)	30 (22.5, 36.8)	41(33, 47.2)	0.067
ALT U/L	30 (19.5 to 57)	26 (20.5 to 32.8)	22 (17.2, 57.5)	0.614
INR	2.2 ± 0.3	2.8 ± 0.3	2.9 ± 0.2	**< 0.001**
Hb g/dL	9.5 ± 1.0	9.7 ± 1.0	9.1 ± 0.9	0.114

Continuous data are presented as the mean ± SD or as the median (25th, 75th percentiles) where appropriate. ALT: alanine aminotransferase; AST: aspartate aminotransferase; CABG: coronary artery bypass graft; GI-bleeding: gastrointestinal bleeding; Hb: hemoglobin; ICU: intensive care unit; INR: international normalized ratio; LAA: left atrium appendage; LDH: lactate dehydrogenase; LVAD: left ventricular assist device; TVR: tricuspid valve replacement

preoperative peAF who underwent LVAD implanta- tion also had an increased risk of mortality (HR: 18.68 (8.04–43.40, $p < 0.001$)) (Fig. 2; Table 3). Preoperative pAF was an independent risk factor for postoperative IS according to univariate and multivariate Cox regression analyses (HR: 4.35 (1.40–13.51, $p = 0.011$)) (Table 4). Sim- ilarly, compared with SR, preoperative peAF was also an independent risk factor for postoperative IS (HR: 14.95 (3.94–56.68, $p < 0.001$)) (Table 4). We then performed a linear regression analysis with RHF as a dependent factor, and after entering age, sex, ICM, DCM, preoperative KD, preoperative creatinine and the preoperative AF status, we found that peAF was an independent risk factor for postoperative RHF (odds ratio: 11.2 (95% CI: 0.72–12.4), $p = 0.003$) (Table 5).

Inverse probability weighting and the estimated average treatment effect

After performing IPTW, we estimated the ATE using SR, pAF and peAF as the treatments and post-LVAD IS as the outcome and found that patients with either pAF or peAF had a significantly greater possibility of developing IS post-LVAD implantation (Table 6). Com- pared with patients with SR, those with pAF had a 15% increased risk of post-LVAD IS, and those with peAF had a 36% increased possibility of developing IS post-LVAD implantation ($p = 0.035$ and $p = 0.004$) (Table 6). We also calculated the ATE for mortality after LVAD implan- tation, and found that compared with those with SR, patients with peAF had a 54% increased risk of mortality ($p < 0.001$). The ATE for post-LVAD RHF did not signifi- cantly differ among the three groups (Table 6).

Discussion

AF is a well-established risk factor for cardiovascular events in the general population [13]. In this investiga- tion, we examined whether preoperative AF affects sur- vival and adverse events during LVAD therapy.

The results of our investigation may be summarized into three main conclusions. Initially, patients with pre- operative peAF who underwent LVAD implantation had an increased likelihood of mortality compared with patients with SR or pAF who underwent LVAD implan- tation. Furthermore, pAF and peAF were identified as distinct factors that independently increase the risk of postoperative IS. Although patients with either pAF or peAF had higher INR values than patients with SR, we did not detect an increased risk of bleeding events in those patients.

Due to the absence of a physiological pulse, patients with a continuous flow (CF)-LVAD experience extremely elevated levels of sympathetic nerve activity [14] as a




Fig. 1 Kaplan–Meier survival curves
pAF: paroxysmal atrial fibrillation; peAF: permanent atrial fibrillation; SR: sinus arrhythmia

Table 3 Univariable and multivariable Cox regression for predicting mortality after LVAD implantation

		All	HR (univariable)	HR (multivariable)
Preoperative rhythm	SR	106 (65.4)	-	-
	pAF	38 (23.5)	2.16 (1.18-3.94, $p=0.012$)	2.62 (1.37-5.02, $p=0.004$)
	peAF	18 (11.1)	10.42 (5.35-20.26, $p<0.001$)	18.68 (8.04-43.40, $p<0.001$)
Females	0	131 (80.9)	-	-
	1	31 (19.1)	0.71 (0.35-1.44, $p=0.342$)	0.53 (0.26-1.11, $p=0.093$)
ICM	0	43 (26.5)	-	-
	1	119 (73.5)	0.72 (0.42-1.23, $p=0.230$)	1.31 (0.72-2.38, $p=0.377$)
DCM	0	119 (73.5)	-	-
	1	43 (26.5)	1.38 (0.81-2.35, $p=0.230$)	NA (NA-NA, $p=$ NA)
Kidney disease	0	107 (66.0)	-	-
	1	55 (34.0)	1.29 (0.78-2.15, $p=0.326$)	0.63 (0.34-1.17, $p=0.144$)
Age	Mean (SD)	61.4 (9.2)	1.03 (1.00-1.07, $p=0.029$)	1.04 (1.01-1.08, $p=0.022$)
Preop creatinine mg/dL	Mean (SD)	1.4 (0.8)	1.21 (0.98-1.50, $p=0.074$)	1.13 (0.82-1.56, $p=0.459$)

SR: sinus arrhythmia; pAF: paroxysmal atrial fibrillation; peAF: permanent atrial fibrillation; ICM: ischemic cardiomyopathy; DCM: dilated cardiomyopathy

consequence of baroreceptor unloading [15]. This may contribute to overt hypertension and difficulty in control- ling blood pressure due to the increased total peripheral resistance through the α1 receptor [16, 17]. Endothelial dysfunction is a cellular consequence of CF-LVADs that develops immediately following implantation, progres- sively worsens, and is linked to deleterious cardiovascular events in this population [17, 18].




Fig. 2 Multivariate Cox regression hazard ratio plots for predicting mortality
DCM: dilated cardiomyopathy; pAF: paroxysmal atrial fibrillation; peAF: permanent atrial fibrillation; SR: sinus arrhythmia

Table 4 Univariable and multivariable Cox regression for predicting ischemic stroke after LVAD implantation

		All	HR (univariable)	HR (multivariable)
Preoperative rhythm	SR	106 (65.4)	-	-
	pAF	38 (23.5)	3.65 (1.28-10.41, $p = 0.016$)	4.35 (1.40-13.51, $p = 0.011$)
	peAF	18 (11.1)	9.48 (2.94-30.56, $p < 0.001$)	14.95 (3.94-56.68, $p < 0.001$)
Female	0	131 (80.9)	-	-
	1	31 (19.1)	0.76 (0.22-2.59, $p = 0.656$)	0.49 (0.14-1.77, $p = 0.277$)
ICM	0	43 (26.5)	-	-
	1	119 (73.5)	1.33 (0.44-4.02, $p = 0.610$)	2.60 (0.81-8.37, $p = 0.110$)
DCM	0	119 (73.5)	-	-
	1	43 (26.5)	0.75 (0.25-2.26, $p = 0.610$)	NA (NA-NA, $p =$ NA)
Kidney disease	0	107 (66.0)	-	-
	1	55 (34.0)	1.73 (0.70-4.26, $p = 0.234$)	0.92 (0.31-2.70, $p = 0.883$)
Age	Mean (SD)	61.4 (9.2)	1.03 (0.97-1.08, $p = 0.328$)	1.01 (0.96-1.07, $p = 0.639$)
Preop creatinine mg/dL	Mean (SD)	1.4 (0.8)	1.24 (0.89-1.73, $p = 0.206$)	1.22 (0.67-2.25, $p = 0.515$)

SR: sinus arrhythmia; pAF: paroxysmal atrial fibrillation; peAF: permanent atrial fibrillation; ICM: ischemic cardiomyopathy; DCM: dilated cardiomyopathy

Table 5 Linear regression revealed that right heart failure was a dependent factor

Model Coefficients – RHF							
Predictor	**Estimate**	**SE**	**Z**	**p**	**Odds ratio**	**95% Confidence Interval Lower upper**	
Intercept	-4.22	**2.10**	**-2.01**	**0.045**	**0.01**	**0.00**	**0.90**
ICM	2.86	**1.15**	**2.49**	**0.053**	**17.45**	**1.84**	**33.41**
DCM	-	**-**	**-**	**-**	**-**	**-**	**-**
Kidney disease	0.13	**0.63**	**0.20**	**0.838**	**1.14**	**NA**	**NA**
Preop creatinine mg/dL	0.47	**0.34**	**1.37**	**0.170**	**1.59**	**0.33**	**3.89**
Age	-0.02	**0.03**	**-0.84**	**0.403**	**0.98**	**0.82**	**3.12**
Female	-1.30	**0.88**	**-1.47**	**0.142**	**0.27**	**0.92**	**1.03**
Groups							
pAF - SR	1.04	**0.69**	**1.49**	**0.135**	**2.82**	**0.05**	**1.54**
peAF - SR	2.54	**0.84**	**3.02**	**0.003**	**11.02**	**0.72**	**12.84**

SE: standard error; Z: Z test; SR: sinus arrhythmia; pAF: paroxysmal atrial fibrillation; peAF: permanent atrial fibrillation; ICM: ischemic cardiomyopathy; DCM: dilated cardiomyopathy

Table 6 Average treatment effect after inverse probability weighting

Post-LVAD mortality					
ATE	Coef.	Robust Std. Err.	*P*	95% Confidence interval	
Groups				Upper	Lower
pAF vs. SR	0.08	0.099	0.384	-0.11	0.28
peAF vs. SR	0.54	0.068	< 0.001	0.41	0.68
Post-LVAD ischemic stroke					
ATE	Coef.	Robust Std. Err.	*P*	95% Confidence interval	
Groups				Upper	Lower
pAF vs. SR	0.15	0.07	0.035	0.01	0.30
peAF vs. SR	0.36	0.12	0.004	0.11	0.60
Post-LVAD right heart failure					
ATE	Coef.	Robust Std. Err.	*P*	95% Confidence interval	
Groups				Upper	Lower
pAF vs. SR	0.02	0.06	0.730	-0.10	0.15
peAF vs. SR	0.01	0.11	0.881	-0.19	0.22

pAF: paroxysmal atrial fibrillation; peAF: permanent atrial fibrillation; SR: sinus arrhythmia; Std. Err.: standard error

The direct contact between blood and the foreign material of an LVAD results in a hypercoagulable state, as well as an increase in inflammatory markers that can pro- mote altered coagulation profiles and predispose patients to platelet activation [19, 20].

Although some minor deviations occur among insti- tutions due to variations in philosophy and practices, patients are typically prescribed warfarin anticoagula- tion therapy with international normalized ratio (INR) objectives of 2.0–3.0 in addition to antiplatelet therapy [20]. Some of these minor differences are related to the approach used for the cessation of anticoagulation therapy during an episode of gastrointestinal bleeding [20]. These differences include the following: (1) active reversal of the INR upon admission for gastrointesti- nal bleeding versus observation and simple cessation of anticoagulation; (2) discontinuation of antiplatelet medi- cations versus continuation of either aspirin or a short- term alternative such as a glycoprotein IIb/IIIa inhibitor; and (3) timing of anticoagulation resumption after treat- ment for GI bleeding [20].

Although no universally applicable approach has been established, numerous authors have reported a low risk of thromboembolic events (TEs) with mild anticoagula- tion, and most TE events occur at an INR of less than 1.5 [20, 21, 22]. Additionally, the complete cessation of war- farin therapy for an extended period without any adverse events has been documented [23].

Regrettably, no rigorous clinical trials that would inform treatment algorithms have been conducted, and thus the most effective anticoagulation strategy remains to be determined. Intuitively, the same approach may not be appropriate for patients with distinct clinical charac- teristics [20]. The function of AF in this context has not been the subject of any prior research [20].

The precise mechanism by which AF increases the risk of TE events originating in the left atrium is not completely understood. Recent research has shown that

platelet activation and thrombin production occur within the left atrium [24].

It is undisputed that AF is a prothrombotic condition, and the intensity of this state is undoubtedly exacerbated by the LVAD implant. Consequently, it may be necessary to implement modified anticoagulation strategies. In the present era, we have devoted more attention to the left atrial appendage in the context of patients with preop- erative AF from a surgical perspective [25]. Currently, we remove the left atrial appendage from patients who have a thrombus in this location, as evidenced by preopera- tive echocardiography. In this series, this step was neces- sary in only nine patients. Although only a few existing studies support this practice, it may be beneficial to pro- phylactically remove the left atrial appendage in patients with preoperative AF to reduce the risk of stroke [20, 25]. Although the most prevalent regimen for patients fol- lowing LVAD implantation is warfarin anticoagulation and aspirin therapy, no significant clinical trials have examined alternative anticoagulants in this population. In contrast, the efficacy and favorable adverse effect pro- files of newer anticoagulants have been demonstrated to be preferable to those of warfarin in patients with AF in three landmark trials [20].

The risk of thromboembolic events is a significant concern among patients with an LVAD, and conflict- ing clinical data exist regarding whether AF elevates this risk. Although preoperative AF has been linked to an increased risk of thromboembolism [20], other studies have reported a reduced association or no increased risk [8, 9, 10].

A significant finding of our study is that patients with pAF or peAF experienced IS at markedly higher INR val- ues than did those with SR, which is consistent with the findings of Enriquez et al. [34]. Interestingly, although patients with pAF or peAF had higher INR values than did patients with SR, we did not detect an increased incidence of bleeding events, similar to the findings of Enriquez et al. [34]. This finding supports the notion that acquired von Willebrand disease (aVWd) significantly contributes to bleeding in patients with LVADs and that a minor variation in the target INR may be less impact- ful [35]. In our study, we found that both pAF and peAF are independent risk factors for postoperative IS. This aligns with a previous study that investigated throm- boembolism and AF in patients with continuous-flow LVADs, where Stulak et al. [20] reported a heightened risk of thromboembolism associated with preoperative AF (HR: 1.89; $p < 0.01$). The precise mechanism by which AF increases the risk of TE events in the left atrium (LA) remains inadequately understood. AF meets the condi- tions of Virchow's triad, which is essential for thrombus formation: blood stasis, endothelial dysfunction, and activation of the coagulation cascade [36]. Endothelial dysfunction is an additional pertinent element of Vir- chow's triad that has been identified in patients with AF through the measurement of various markers of endo- thelial perturbation, including von Willebrand factor and E-selectin [37]. Clotting activation, which represents the third component of Virchow's triad, potentially contrib- utes to thrombosis-related clinical events in patients with atrial fibrillation [38]. Numerous studies indicate that AF can lead to a hypercoagulable state, as evidenced by elevated plasma levels of F1 + 2, D-dimer, and fibrino- gen [39, 40]. Platelet activation and thrombin generation have been shown to occur within the left atrium [41]. AF undeniably signifies a prothrombotic condition, which is unequivocally exacerbated with VAD implantation. Consequently, modified anticoagulation methods may be necessary. From a surgical perspective, increased focus on the LAA has been observed in the contemporary management of patients with preoperative AF.

The connection between AF and HF has long been established. Through decreases in the diastolic filling time, reductions in ventricular filling through the loss of atrial systole, and impacts on systolic function, AF can exacerbate the symptoms of HF [26, 27, 28]. On the con- trary, decompensated HF can exacerbate AF and cause ventricular tachycardia. Given this interaction, it is not unexpected that AF has been linked to higher hospital- ization and mortality rates in patients with HF [27, 28, 29]. The findings of our study closely align with those of the SOLVD study [27]. In our study, only patients with peAF had significantly lower survival rates than did patients with preoperative SR and patients with pAF according to the IPTW analysis. Our findings regard- ing poorer survival of patients with preoperative AF are in accordance with those of a large meta-analysis per- formed by Tantrachoti et al. [30], who analyzed seven retrospective investigations that included 5823 patients with LVADs (AF 1589; SR 4234). The median follow-up duration was between seven and twenty-four months. Pooled analysis revealed a significantly greater mortal- ity risk in patients with preoperative AF who underwent LVAD implantation than in those with SR (risk ratio [RR] 1.16, 95% CI 1.05-1.28; I2 = 0%) [30]. The results of previ- ous studies are conflicting; Antonides et al. [7] used data from a large European multicenter registry to clarify the impact of preoperative AF on outcomes during LVAD support. Antonides et al. [7] reported that patients with AF had a noticeably poorer survival rate than did those with SR; however, the presence of preoperative AF was not significantly independently associated with lower survival in the multivariable model of this investigation.

LVAD management may be affected by our findings in that patients benefit from more aggressive rhythm man- agement to reduce the AF burden. Surgical CryoMAZE,

liberal antiarrhythmic medication use, and catheter abla- tion during LVAD placement might be considered.

While the medical management of AF in the non- LVAD population is well documented, data on the opti- mal management of AF following LVAD implantation are lacking [31]. Specifically, the influence of AF on hemody- namics and symptoms in patients with a CF-LVAD is not well understood. Consequently, ascertaining the advan- tages of any specific treatment is difficult [31]. In this context, the medical management of AF in patients with an LVAD is based on either the extrapolation of preestab- lished guidelines in non-LVAD populations or on limited retrospective or single-center reports [31].

Anticoagulation is necessary for patients with LVADs to mitigate the risk of pump thrombus and TEs, pro- vided that contraindications are not present [32]. The INR target in these patients is generally not affected by AF [31], and rate control is a critical management strat- egy for these patients [31]. Although the reverse remod- eling effects of β-blockers in patients with HF with reduced ejection fraction (HFrEF) [31, 33] do not extend to those with LVADs, 1 of the 3 β-blockers approved for patients with heart failure with a reduced ejection frac- tion (carvedilol, bisoprolol, or metoprolol succinate) [34] is generally continued in the absence of any clear contra- indication (e.g., hypotension, orthostasis, severe RV dys- function). Perhaps the most frequently employed agent for this purpose, β-blockers can be used to achieve rate control in patients with AF and an LVAD [31]. Digoxin is frequently incorporated into medical management strategies for patients with HFrEF after LVAD implanta- tion and is frequently used as an adjunct to goal-directed medical therapy to reduce the rate of HF-related hospital- izations [35]. The combination of digoxin and β-blockers has been demonstrated to be an effective strategy for achieving AF rate control at rest and during exercise [36]. This strategy may also be considered for patients with AF and an LVAD [31]. The optimal heart rate or rate control strategy for LVAD recipients is unclear and may differ from that of patients without LVADs due to numerous physiological differences [31].

Study limitations

Our study has multiple limitations. First, the data in this study are constrained by documentation in patients' medical charts because of its retrospective and non- randomized design, and thus the study is susceptible to selection bias and confounding factors. This study also has a limited sample size and a small number of patients and outcomes. Therefore, the results should be viewed as preliminary and should serve only to generate hypoth- eses. 68% of the patients in our study received HMII implants, which accounted for only 31%, and all patients had international normalized ratio (INR) goals based on our institutional protocol. Therefore, our findings of bleeding and thromboembolic events may not be appli- cable to different INR protocols or other devices. Fur- thermore, our study yielded significantly favorable results when a subgroup analysis was conducted. Therefore, the findings are less meaningful.

Conclusions

Preoperative peAF is associated with poorer survival compared with SR after LVAD implantation. Both pAF and peAF are independent risk factors for a higher inci- dence of IS post-LVAD.

Abbreviations

AF	Atrial fibrillation
ALT	Alanine aminotransferase
AST	Aspartate aminotransferase
BMI	Body mass index
BSA	Body surface area
COPD	Chronic obstructive pulmonary disease
CVD	Cerebrovascular disease
DCM	Dilated cardiomyopathy
DM	Diabetes mellitus
eCV	Electric cardioversion
EF	Ejection fraction
Hb	Hemoglobin
HR	Hazard ratio
ICM	Ischemic cardiomyopathy
ICU	Intensive care unit
INR	International normalized ratio
INTERMACS	Interagency Registry for Mechanically Assisted Circulatory Support
KD	Kidney disease
LAA	Left atrium appendage
LDH	Lactate dehydrogenase
NT-pro-BNP	N-terminal pro-brain natriuretic peptide
OR	Odds ratio
PAD	Peripheral arterial disease
pAF	Paroxysmal atrial fibrillation
PCI	Percutaneous coronary intervention
peAF	Permanent atrial fibrillation
PH	Pulmonary hypertension
RHF	Right heart failure
SR	Sinus arrhythmia
STS-Intermacs	Society of Thoracic Surgeon Interagency Registry of Mechanically Assisted Circulatory Support

Acknowledgements

Not aplicable.

Author contributions

RAK: Writing the first version of the manuscript, original draft, Visualization, Validation, Software, Investigation, Formal Analysis, Data curation, Conceptualization. AK: Writing - review & editing, Visualization, Validation, Software, Investigation, Formal Analysis, Data curation. NM: Writing - review & editing, Supervision, Methodology, Resources, Conceptualization. AM: Writing, review, editing, supervision, project administration, and surgery. AB: Writing - review & editing, supervision, project administration. YIM: Writing - review & editing, Data curation, AAH: Writing - review & editing, Resources, MS: Writing - review & editing, Software, Resources. RZ: Conceptualization, Writing - review & editing, Validation, Supervision, Software, Resources, Project administration, Methodology, performed surgery. MAK: Writing - review & editing, visualization, validation, supervision, software, resources, project administration, methodology, data curation, conceptualization, and surgery.

Funding

Open Access funding enabled and organized by Projekt DEAL.
This study received no external funding.

Data availability
The anonymized data collected are available as open data in Figshare with the identifier https://doi.org/10.6084/m9.figshare.27796389.

Declarations

Ethics approval and consent to participate
Our retrospective data analysis received approval from the ethics committee of our institution (Ethikkommission-RWTH Aachen, IRBP 10/2014, EK151/09-Version-1.3). Due to the retrospective nature of our study, informed consent was waived by our institutional ethics board.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests.

Author details
[1]Faculty of Medicine, Clinic for Cardiology, Angiology, and Intensive Care Medicine, RWTH Aachen University, University Hospital Aachen, Aachen, Germany
[2]Faculty of Medicine, Department of Cardiac Surgery, RWTH Aachen University, University Hospital Aachen, Aachen, Germany
[3]Heart Center Trier, Department of Cardiovascular and Thoracic surgery, Barmherzige Brueder Hospital, Trier, Germany
[4]Department of Cardiovascular Surgery, Klinikum Dortmund gGmbH, Dortmund, Germany
[5]Witten/Herdecke University, Witten, Germany
[6]Department of Cardiothoracic Surgery, St. Johannes Hospital, Dortmund, Germany
[7]Department of Radiology, St. Augustinus Hospital, Dueren, Germany
[8]Department of Cardiac Surgery, Klinikum Links der Weser, Bremen, Germany

Received: 16 November 2024 / Accepted: 17 March 2025
Published online: 29 March 2025

References

1. Jorde UP, Kushwaha SS, Tatooles AJ, Naka Y, Bhat G, Long JW, Horstmanshof DA, Kormos RL, Teuteberg JJ, Slaughter MS, et al. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency registry for mechanically assisted circulatory support). J Am Coll Cardiol. 2014;63(17):1751–7.
2. Mehra MR, Goldstein DJ, Cleveland JC, Cowger JA, Hall S, Salerno CT, Naka Y, Horstmanshof D, Chuang J, Wang A, et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial. JAMA. 2022;328(12):1233-42.
3. Molina EJ, Shah P, Kiernan MS, Cornwell WK 3rd, Copeland H, Takeda K, Fer- nandez FG, Badhwar V, Habib RH, Jacobs JP et al. The Society of Thoracic Sur- geons Intermacs 2020 Annual Report. Ann Thorac Surg. 2021;111(3):778–792.
4. Stulak JM, Davis ME, Haglund N, Dunlay S, Cowger J, Shah P, Pagani FD, Aaronson KD, Maltais S. Adverse events in contemporary continuous-flow left ventricular assist devices: a multi-institutional comparison shows significant differences. J Thorac Cardiovasc Surg. 2016;151(1):177–89.
5. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019;140(2):e125–51.
6. Dries D, Exner D, Gersh B, Domanski M, Waclawiw M, Stevenson L. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol. 1998;32(3):695–703.
7. Antonides CFJ, Yalcin YC, Veen KM, Muslem R, De By T, Bogers A, Gustafsson F, Caliskan K. Survival and adverse events in patients with atrial fibrillation at left ventricular assist device implantation: an analysis of the European registry for patients with mechanical circulatory support. Eur J Cardiothorac Surg. 2022;61(5):1164-75.
8. Imamura T, Kinugawa K, Ono M, Kinoshita O, Fukushima N, Shiose A, Matsui Y, Yamazaki K, Saiki Y, Usui A, et al. Implication of preoperative existence of atrial fibrillation on hemocompatibility-related adverse events during left ventricular assist device support. Circ J. 2019;83(6):1286–92.
9. Pedde D, Soltani S, Stein J, Tsyganenko D, Muller M, Schonrath F, Falk V, Pota- pov EV. Impact of preoperative atrial fibrillation on thromboembolic events and pump thrombosis in long-term left ventricular assist device therapy. Eur J Cardiothorac Surg. 2020;57(2):325–30.
10. Kittipibul V, Rattanawong P, Kewcharoen J, Chongsathidkiet P, Vutthikraivit W, Kanjanahattakij N. Atrial fibrillation is not associated with thromboembolism in left ventricular assist device patients: a systematic review and meta-analy- sis. ASAIO J. 2019;65(5):456–64.
11. INTERMACS Adverse Event Definitions. [https://intermacs.kirso.net/intermac s-documents/]
12. Bettega F, Mendelson M, Leyrat C, Bailly S. Use and reporting of inverse-probability-of-treatment weighting for multicategory treatments in medical research: a systematic review. J Clin Epidemiol. 2024;170:111338.
13. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, et al. 2023 ACC/ AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2024;149(1):e1–156.
14. Markham DW, Fu Q, Palmer MD, Drazner MH, Meyer DM, Bethea BT, Hastings JL, Fujimoto N, Shibata S, Levine BD. Sympathetic neural and hemodynamic responses to upright tilt in patients with pulsatile and nonpulsatile left ventricular assist devices. Circulation: Heart Fail. 2013;6(2):293–9.
15. Cornwell WK 3rd, Tarumi T, Stickford A, Lawley J, Roberts M, Parker R, Fitzsim- mons C, Kibe J, Ayers C, Markham D, et al. Restoration of pulsatile flow reduces sympathetic nerve activity among individuals with continuous-flow left ventricular assist devices. Circulation. 2015;132(24):2316–22.
16. Joyner MJ, Charkoudian N, Wallin BG. Sympathetic nervous system and blood pressure in humans: individualized patterns of regulation and their implica- tions. Hypertension. 2010;56(1):10–6.
17. Gopinathannair R, Cornwell WK, Dukes JW, Ellis CR, Hickey KT, Joglar JA, Pagani FD, Roukoz H, Slaughter MS, Patton KK. Device therapy and arrhythmia management in left ventricular assist device recipients: a scientific statement from the American Heart Association. Circulation. 2019;139(20):e967–89.
18. Hasin T, Matsuzawa Y, Guddeti RR, Aoki T, Kwon TG, Schettle S, Lennon RJ, Chokka RG, Lerman A, Kushwaha SS. Attenuation in peripheral endothelial function after continuous flow left ventricular assist device therapy is associ- ated with cardiovascular adverse events. Circ J. 2015;79(4):770–7.
19. John R, Panch S, Hrabe J, Wei P, Solovey A, Joyce L, Hebbel R. Activation of endothelial and coagulation systems in left ventricular assist device recipi- ents. Ann Thorac Surg. 2009;88(4):1171–9.
20. Stulak JM, Deo S, Schirger J, Aaronson KD, Park SJ, Joyce LD, Daly RC, Pagani FD. Preoperative atrial fibrillation increases risk of thromboembolic events after left ventricular assist device implantation. Ann Thorac Surg. 2013;96(6):2161–7.
21. Menon AK, Götzenich A, Sassmannshausen H, Haushofer M, Autschbach R, Spillner JW. Low stroke rate and few thrombo-embolic events after heart- mate II implantation under mild anticoagulation†. Eur J Cardiothorac Surg. 2012;42(2):319–23.
22. Boyle AJ, Russell SD, Teuteberg JJ, Slaughter MS, Moazami N, Pagani FD, Frazier OH, Heatley G, Farrar DJ, John R. Low thromboembolism and pump thrombosis with the heartmate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplantation. 2009;28(9):881–7.
23. Zayat R, Khattab MA, Grottke O, Honickel M, Goetzenich A, Moza A, Stoppe C, Autschbach R, Tewarie L. Survival of heartmate II patients despite cessation of anticoagulation - outcomes and hemostatic analysis. Circ J. 2018;82(5):1309–18.
24. Lim HS, Willoughby SR, Schultz C, Gan C, Alasady M, Lau DH, Leong DP, Brooks AG, Young GD, Kistler PM, et al. Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm. J Am Coll Cardiol. 2013;61(8):852–60.

25. Kewcharoen J, Shah K, Bhardwaj R, Contractor T, Turagam MK, Mandapati R, Lakkireddy D, Garg J. Surgical left atrial appendage occlusion in patients with left ventricular assist device. Pacing Clin Electrophysiol. 2022;45(4):567–70.
26. Ruddox V, Sandven I, Munkhaugen J, Skattebu J, Edvardsen T, Otterstad JE. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: a systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24(14):1555–66.
27. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of left ventricular dysfunction. J Am Coll Cardiol. 1998;32(3):695–703.
28. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMur- ray JJ, Puu M, Yusuf S, Pfeffer MA. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006;47(10):1997–2004.
29. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003;91(6a):d2–8.
30. Tantrachoti P, Klomjit S, Vutthikraivit W, Prieto S, Gongora E, Nair N. Impact of preoperative atrial fibrillation in patients with left ventricular assist device: a systematic review and meta-analysis. Artif Organs. 2019;43(12):1135–43.
31. Reddy YNV, Borlaug BA, Gersh BJ. Management of atrial fibrillation across the spectrum of heart failure with preserved and reduced ejection fraction. Circulation. 2022;146(4):339–57.
32. Swetz KM, Freeman MR, Mueller PS, Park SJ. Clinical management of continu- ous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transpl. 2010;29(9):1081.
33. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, et al. 2014 AHA/ACC/HRS guide- line for the management of patients with atrial fibrillation. Circulation. 2014;130(23):e199–267.
34. Cintron G, Johnson G, Francis G, Cobb F, Cohn JN. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA cooperative studies group. Circulation. 1993;87(6 Suppl):Vi17–23.
35. Jennings DL, Jones MC, Lanfear DE. Assessment of the heart failure pharma- cotherapy of patients with continuous flow left-ventricular assist devices. Int J Artif Organs. 2012;35(3):177–9.
36. Fauchier L, Grimard C, Pierre B, Nonin E, Gorin L, Rauzy B, Cosnay P, Babuty D, Charbonnier B. Comparison of beta blocker and digoxin alone and in com - bination for management of patients with atrial fibrillation and heart failure. Am J Cardiol. 2009;103(2):248–54.
37. Nightingale T, Cutler D. The secretion of von Willebrand factor from endothe- lial cells; an increasingly complicated story. J Thromb Haemost. 2013;11(Suppl 1):192–201.
38. Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of thrombogen- esis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J. 1995;73(6):527–33.
39. Mitusch R, Siemens HJ, Garbe M, Wagner T, Sheikhzadeh A, Diederich KW. Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost. 1996;75(2):219–23.
40. Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart. 1997;77(5):407–11.
41. Lim HS, Willoughby SR, Schultz C, Gan C, Alasady M, Lau DH, et al. Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm. J Am Coll Cardiol. 2013;61(8):852–60.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Erklärung § 5 Abs. 1 zur Datenaufbewahrung

Hiermit erkläre ich, dass die dieser Dissertation zu Grunde liegenden Originaldaten

- in der ***Klinik für Herzchirurgie*** des Universitätsklinikums

Aachen hinterlegt sind.

Erklärung gemäß § 5 Abs. (1) und (2), und § 11 Abs. (3) 12. der Promotionsordnung

Hiermit erkläre ich, **Rami Al-Khusein,** an Eides statt, dass ich den wesentlichen Anteil an der Publikation:
Al-Khusein R, Kolashov A, Marx N, Moza A, Abugameh A, Mohamed YI, Al-Ahmed A, Shoaib M, Dogan L, Zayat R, Khattab MA. The impact of preoperative atrial fibrillation on survival and outcomes in heartmate II and heartmate 3 patients. BMC Cardiovasc Disord. 2025 Mar 29;25(1):236. doi: 10.1186/s12872-025-04680-1. PMID: 40158072; PMCID: PMC11954273. https://doi.org/10.3390/jcm14103613**.** Die Anteile an der Arbeit waren wie folgt:

**Bitte Namen angeben ----------> **	R. Al-Khusein	A. Kolashov	N. Marx	A. Moza	A. Abugameh	YI. Mohamed	A. Al-Ahmed	M. Shoaib	L. Dogan	R. Zayat	M.A. Khattab	Summe (%)
Studienüberwachung				20	20	10			10	20	20	100
Studiendesign/Konzeption	30	20			10				10	10	20	100
Untersuchung der Probanden	65	35										100
Blut Abnahme	60	40										100
Durchführen von bio-ADM und penKid Messungen	50	30			10	10						100
Methodology				20	15	15				25	25	100
Datenerhebung	60	40										100
Datenauswertung	60	40										100
Validation	40	20			10	10				10	10	100
Statistische Auswert.	60	30									10	100
Bereitstellung von Materialien			10	10	10	10		50	10			100
Interpretation der Datenauswertung	55	20								10	15	100
Visualization	50	30					20					100
Verfassung des Manuskripts	**100**											100
writing—review & editing	10	10	10	10	10	10	10		10	10	10	100

Aus diesem wesentlichen Anteil ergibt sich selbstverständlich die Stellung als geteilte Erstautor in der ersten Position

Unterschrift der Doktorand und korrespondierender Author (Rami Al-Khusein)

Als Doktorvater und bestätige ich die Angaben von Herr Al-Khusein

Unterschrift des Doktorvaters (PD Dr. med. R. Zayat)

Ich schließe mich der Erklärung von PD Dr. med. R. Zayat als Koautor an

Dr. med. A. Kolashov Dr. med. A. Abugameh PD Dr. med. A. Moza

Prof. Dr. med. N. Marx YI. Mohamed Dr. med. M. Shoaib

A. Al-Ahmed L. Dogan Dr. med. M.A. Khattab